ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

ImmuCell Corporation (NASDAQ:ICCC) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $8.96 and traded as high as $10.02. ImmuCell shares last traded at $9.84, with a volume of 15,550 shares trading hands.

Analyst Upgrades and Downgrades

ICCC has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of ImmuCell from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 18th. Wall Street Zen raised ImmuCell to a “strong-buy” rating in a report on Saturday, June 27th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

ImmuCell Price Performance

The stock has a market capitalization of $90.00 million, a P/E ratio of 123.89 and a beta of 0.54. The firm’s fifty day moving average is $10.56 and its 200-day moving average is $9.01. The company has a current ratio of 4.75, a quick ratio of 2.71 and a debt-to-equity ratio of 0.22.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings data on Thursday, August 13th. The biotechnology company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.15. ImmuCell had a net margin of 2.57% and a return on equity of 2.69%. The firm had revenue of $7.19 million for the quarter, compared to analysts’ expectations of $5.40 million.

Insider Buying and Selling

In other ImmuCell news, CEO Boekhorst Paul Francis Oliv Te purchased 8,000 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average cost of $9.49 per share, with a total value of $75,920.00. Following the acquisition, the chief executive officer directly owned 17,785 shares of the company’s stock, valued at approximately $168,779.65. This trade represents a 81.76% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 5.70% of the stock is currently owned by company insiders.

Institutional Trading of ImmuCell

Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in shares of ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 2,907 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in ImmuCell by 3.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock worth $355,000 after buying an additional 1,749 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in ImmuCell by 199.6% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after acquiring an additional 24,303 shares during the last quarter. Finally, Militia Capital Management LLC bought a new stake in ImmuCell during the 1st quarter worth about $114,000. Institutional investors own 13.47% of the company’s stock.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.